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INTRODUCTION 
Sickle Cell Anemia (SCA) is an inherited blood disorder characterized by the presence of hemoglobin S (Hb S). This disease is caused 
by a single mutation in the beta-globin gene with a corresponding amino acid substitution at the sixth position of the beta-globin 
chain. The easily ability of Hb S to polymerize in deoxygenated conditions gives rise to abnormal sickled red blood cells (Figure 1) 
(Rees et al, 2010). Vaso-occlusion and hemolytic anemia are the major features of this disease, however SCA patients present 
clinical and hematologic variability that cannot be only explained by the single mutation in the beta-globin gene. Others genetic 
modifiers and environmental effects are important in the clinical phenotype (Steinberg & Sebastiani, 2012). SCA patients present 
arginine deficiency that contributes to a lower nitric oxide (NO) bioactivity. The amino acid citrulline increases arginine levels and 
promotes NO production (Kaore et al, 2013). 
The aim of this work was to determine the association between hematological or biochemical parameters and genetic variants 
from candidate genes, in SCA patients. Effects of oral citrulline supplementation in SCA were also considered. 
Figure 1 - Peripheral blood smear of a patient with SCA. The 
arrows point to two sickled erythrocytes (Adapted from Rees 
et al, 2010).     
METHODS 
Subjects: 26 paediatric SCA patients (mean age of 8.58 years) followed-up in Hospital de Dona Estefânia, in Lisbon. 
Hematological or biochemical parameters: Hb S, total Hb, red cell distribution width (RDW), levels of leukocytes, levels of neutrophils, transmembrane reductase, 
methemoglobin reductase, myeloperoxidase (MPO), serum lactate dehydrogenase (LDH), total bilirubin and reticulocyte count. 
Candidate genes: BCL11A, HBA, HBB cluster, HMOX1, eNOS, MTHFR and MPO.  
Citrulline supplementation: The citrulline was given orally in daily doses of approximately 0.1 g/kg for 6 months. 
Statistical analysis: Association studies were performed using T test/ ANOVA parametric tests or Mann-Whitney/Kuskal-Wallis non-parametric tests. ANOVA, Kuskal-Wallis 
and Spearman's correlation were used to measure differences between control (before citrulline intake) and months 1, 3 and 6 of citrulline supplementation. All tests were 
performed with SPSS 22.0 software. 
RESULTS  
• The following significant associations were observed (Table 1, 2 and 3, Figure 2, 3 and 4). 
• Results from this study show a significant statistical association between some parameters and genetic variants at eNOS gene. An increased reticulocyte count and high 
serum lactate dehydrogenase levels were associated with both the rs2070744_TT and the rs1799983_GG genotypes at eNOS gene and high levels of neutrophils were 
associated with the eNOS4a allele .  
• A symptomatic improvement was observed in patients with citrulline supplementation.   
 CONCLUSIONS 
Our findings suggest that polymorphisms in the eNOS gene may act as genetic modifiers of the haemolysis, which could provide utility for the prediction of increased 
susceptibility to haemolysis-related complications.  
Furthermore, our results reinforce the importance of nitric oxide (NO) bioactivity in SCA. We presume that NO, and possible its precursors such as arginine or 
citrulline, might be used as pharmacological tools to improve the quality of life of these patients.  
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Figure 2 - Box plots of the distribution of reticulocyte count (a) and LDH level (b) in  rs2070744 genotypes (TT and CT) 
at eNOS gene. 
Figure 3 - Box plots of the distribution of reticulocyte count (a) and LDH level (b) in rs1799983 genotypes (GG and 
GT/TT) at eNOS gene. 
Figure 4 - Box plot of the distribution of levels of neutrophils in the  presence or absence of eNOS4a allele at eNOS 
gene. 
Table 3 - Association between the parameter levels of neutrophils and the  presence or absence 
of eNOS4a allele at eNOS gene 
Parameter Presence of 4a allele Absence of 4a allele p-value 
 
Levels of neutrophils (cell/μL) 
 
 
5942,14 ± 1800,85 (7) 
 
 
3140,00 ± 1417,78 (3) 
 
0,0451 
 
1T test - Mean ±  standard deviation (n – sample size) 
 
 
 
 Table 1 - Association between the parameters reticulocyte count and LDH and rs2070744 genotypes 
(TT and CT) at eNOS gene 
Parameters TT CT p-value 
Reticulocyte count (%) 9.56 ± 3.43 (13) 
 
6.12 ± 2.50 (10) 
 
0.0151 
LDH (U/L) 
 
490.00; 410-793 (7) 
 
371.50; 328-451 (4) 0.0422 
1T test - Mean ±  standard deviation (n – sample size) 
2Mann-Whitney test - Median; minimum - maximum (n – sample size) 
 
 
Table 2 - Association between the parameters reticulocyte count and LDH and rs1799983 genotypes 
(GG and GT/TT) at eNOS gene 
Parameters GG GT/TT p-value 
Reticulocyte count (%) 9.20 ± 3.21 (17) 
 
4.53 ± 1.75 (5) 
 
0.0061 
LDH (U/L) 
 
490.00; 410-793 (7) 
 
371.50; 328-451 (4) 0.0422 
1T test - Mean ±  standard deviation (n – sample size) 
2Mann-Whitney test - Median; minimum - maximum (n – sample size) 
 
 
 
